Program : GRC 10693 |
Phase I Complete
|
|
|
| Target / Indication |
A (CB-2) Receptor Agonist indicated for the
treatment of Neuropathic Pain, Osteoarthritis
and other Inflammatory Pain. |
| Highlights |
| |
|
The only selective CB-2 molecule currently reported in clinical development following the oral route of administration. |
| |
|
A potential first-in-class opportunity. |
| |
|
Highly efficacious in pain models. |
| |
|
Phase I trials complete. Data very encouraging. |
| |
|
Proof of mechanism established as a part of Phase 1. |
|
| Market Opportunity |
| |
|
Neuropathic Pain Market: USD 5 bn; >40mn patients. |
| |
|
Osteoarthritis Market: USD 4 bn; >20 mn patients. |
|
| Potential Peak Sales |
USD 2 bn worldwide. |
|
|
|
| Target / Indication |
A TRPV3 Antagonist indicated for Osteoarthritic pain, Neuropathic pain and urinary incontinence. |
| Highlights |
| |
|
Globally the first TRPV3 molecule to enter clinical trials.
|
| |
|
Out-licensed to Sanofi � Aventis. Total deal size USD 325 million |
| |
|
Currently undergoing Phase I trials in the UK |
| |
|
The molecule is highly efficacious as compared to current gold standard molecules (Pregabalin, Gabapentin) as seen in animal models.
|
| |
|
It is non-habit forming and thus presents a better option for pain therapy .
|
|
| Market Opportunity |
| |
|
Osteoarthritis Market: USD 4 bn; >20 mn patients. |
| |
|
Neuropathic Pain Market: USD 5 bn; >40mn patients. |
|
| Potential Peak Sales |
USD 3 bn worldwide. |
|
